OR WAIT null SECS
Roche has revealed the positive topline results from it Phase III trial assessing the investigational antibody cocktail of casirivimab and imdevimab in high-risk non-hospitalized COVID-19 patients.
Roche has revealed the positive topline results from it Phase III trial assessing the investigational antibody cocktail of casirivimab and imdevimab in high-risk non-hospitalized COVID-19 patients in a March 23, 2021 press release.
The combination antibody treatment was found to reduce the risk of hospitalization or death in high-risk COVID-19 patients by a significant amount when compared with placebo. The antibody cocktail met all key secondary endpoints in the Phase III trial, including the ability to reduce symptom duration by four days.
“Today's results show the important medical benefit casirivimab and imdevimab may provide to people with COVID-19 by significantly reducing their risk of hospitalization and death,” said Levi Garraway, Roche’s chief medical officer and head of Global Product Development, in the press release. “New infections continue to rise globally with over three million reported cases last week, so this investigational antibody cocktail may offer hope as a potential new therapy to high-risk patients—particularly in light of recent evidence showing that casirivimab and imdevimab together retain activity against key emerging variants. Together with our partner Regeneron, we are grateful to the patients and investigators who have participated in ongoing clinical trials and look forward to discussing the growing body of evidence with health authorities and to bringing the treatment to as many people as possible.”